MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting Neuropilin 1.
Kedar Yogi,Epari Sridhar,Naina Goel,Rakesh Jalali,Atul Goel,Aliasgar Moiyadi,Rahul Thorat,Pooja Panwalkar,Atul Khire,Archya Dasgupta,Prakash Shetty,Neelam Shirsat +11 more
- Vol. 2, Iss: 4, pp 334-348
Reads0
Chats0
TLDR
expression of miR-148a to levels comparable to that in the WNT subgroup tumors was found to inhibit proliferation, clonogenic potential, invasion potential and tumorigenicity of medulloblastoma cells.Abstract:
Medulloblastoma, a common pediatric malignant brain tumor consists of four molecular subgroups viz. WNT, SHH, Group 3 and Group 4. MiR-148a is over-expressed in the WNT subgroup tumors, which have the lowest incidence of metastasis and excellent survival among all medulloblastomas. MiR-148a was expressed either in a transient manner using a synthetic mimic or in a stable doxycycline inducible manner using a lentiviral vector in non-WNT medulloblastoma cell lines. Expression of miR-148a to levels comparable to that in the WNT subgroup tumors was found to inhibit proliferation, clonogenic potential, invasion potential and tumorigenicity of medulloblastoma cells. MiR-148a expression in medulloblastoma cells brought about reduction in the expression of NRP1, a novel miR-148a target. Restoration of NRP1 expression in medulloblastoma cells was found to rescue the reduction in the invasion potential and tumorigenicity brought about by miR-148a expression. NRP1 is known to play role in multiple signaling pathways that promote tumor growth, invasion and metastasis. NRP1 expression in medulloblastomas was found to be associated with poor survival, with little or no expression in majority of the WNT tumors. The tumor suppressive effect of miR-148a expression accompanied by the down-regulation of NRP1 makes miR-148a an attractive therapeutic agent for the treatment of medulloblastomas.read more
Citations
More filters
Journal ArticleDOI
MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
Xin Xu,Yun Zhang,J. Jasper,Erik Lykken,Peter B. Alexander,Geoffrey J. Markowitz,Donald P. McDonnell,Qi-Jing Li,Xiao-Fan Wang +8 more
TL;DR: It is found that lower expression of miR-148a is detected in higher-grade tumor samples and correlated with increased likelihood to develop metastases and poor prognosis in subsets of breast cancer patients, particularly those with TNBC.
Journal ArticleDOI
Neuropilins in the Context of Tumor Vasculature
Stephan Niland,Johannes A. Eble +1 more
TL;DR: This review highlights the diverse neuropilin ligands and interacting partners on endothelial cells, which are relevant in the context of the tumor vasculature and the tumor microenvironment.
Journal ArticleDOI
Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1.
Caifeng Gong,Julie Valduga,Alicia Chateau,Mylène Richard,Nadia Pellegrini-Moïse,Muriel Barberi-Heyob,Pascal Chastagner,Cédric Boura +7 more
TL;DR: The results highlighted that targeting NRP-1 with MR438 could be a potential new strategy to differentiate MB stem cells and could limit medulloblastoma progression.
Book ChapterDOI
Neuropilin: Handyman and Power Broker in the Tumor Microenvironment.
Stephan Niland,Johannes A. Eble +1 more
TL;DR: The suitability of various neuropilin-targeting substances and the intervention in neuropILin-mediated interactions is considered as a possible building block of tumor therapy.
Journal ArticleDOI
miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2
Huiyan Cao,Zhiming Liu,Rong Wang,Xiaodong Zhang,Wenfa Yi,Guanyuan Nie,Yong Yu,Guolu Wang,Mingting Zhu +8 more
TL;DR: It is shown that miR-148a was significantly downregulated in RCC tissues and cell lines and AKT2 was confirmed to be a direct target of miR -148a, and mechanistic investigations showed thatmiR- 148a exerted its antitumor activity via inhibition of the AKT pathway in vitro and in vivo.
References
More filters
Journal ArticleDOI
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
TL;DR: A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation and is used to measure proliferative lymphokines, mitogen stimulations and complement-mediated lysis.
Journal ArticleDOI
Molecular Subgroups of Medulloblastoma: The Current Consensus
Michael D. Taylor,Paul A. Northcott,Andrey Korshunov,Marc Remke,Marc Remke,Yoon Jae Cho,Steven C. Clifford,Charles G. Eberhart,D. Williams Parsons,Stefan Rutkowski,Amar Gajjar,David W. Ellison,Peter Lichter,Richard J. Gilbertson,Scott L. Pomeroy,Marcel Kool,Stefan M. Pfister,Stefan M. Pfister +17 more
TL;DR: It is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, and herein is outlined the current consensus nomenclature, and the differences between the medullOBlastoma subgroups.
Journal ArticleDOI
A microRNA DNA methylation signature for human cancer metastasis
Amaia Lujambio,George A. Calin,Alberto Villanueva,Santiago Ropero,Montserrat Sanchez-Cespedes,David Blanco,Luis M. Montuenga,Simona Rossi,Milena S. Nicoloso,William J. Faller,William M. Gallagher,Suzanne A. Eccles,Carlo M. Croce,Manel Esteller +13 more
TL;DR: Findings indicate that DNA methylation-associated silencing of tumor suppressor miRNAs contributes to the development of human cancer metastasis.
Journal ArticleDOI
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
Marcel Kool,Andrey Korshunov,Marc Remke,Marc Remke,David T.W. Jones,Maria Schlanstein,Paul A. Northcott,Yoon Jae Cho,Jan Koster,Antoinette Y N Schouten-van Meeteren,Dannis G. van Vuurden,Steven C. Clifford,Torsten Pietsch,André O. von Bueren,Stefan Rutkowski,Martin G. McCabe,Martin G. McCabe,V. Peter Collins,Magnus Bäcklund,Christine Haberler,Franck Bourdeaut,Olivier Delattre,François Doz,David W. Ellison,Richard J. Gilbertson,Scott L. Pomeroy,Michael D. Taylor,Peter Lichter,Stefan M. Pfister,Stefan M. Pfister +29 more
TL;DR: A meta-analysis of all molecular and clinical data of 550 medulloblastomas brought together from seven independent studies shows how distinct the molecular subtypes are with respect to their transcriptome, DNA copy-number aberrations, demographics, and survival.
Journal ArticleDOI
miR-34 - a microRNA replacement therapy is headed to the clinic.
TL;DR: This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a mi R-34 therapy that may be among the first miRNA mimics to reach the clinic.
Related Papers (5)
MicroRNA profiling in human medulloblastoma
Elisabetta Ferretti,Enrico De Smaele,Agnese Po,Lucia Di Marcotullio,Emanuele Tosi,Maria Salome Bezerra Espinola,Concezio Di Rocco,Riccardo Riccardi,Felice Giangaspero,Alessio Farcomeni,Italo Nofroni,Pietro Laneve,Ubaldo Gioia,Ubaldo Gioia,Elisa Caffarelli,Irene Bozzoni,Irene Bozzoni,Irene Bozzoni,Isabella Screpanti,Isabella Screpanti,Alberto Gulino +20 more
MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.
Livia Garzia,Immacolata Andolfo,Emilio Cusanelli,Natascia Marino,Giuseppe Petrosino,Daniela De Martino,Veronica Esposito,Aldo Galeone,Luigi Navas,Silvia Esposito,Sara Gargiulo,Sarah Fattet,Vittoria Donofrio,Giuseppe Cinalli,Arturo Brunetti,Luigi Del Vecchio,Paul A. Northcott,Olivier Delattre,Michael D. Taylor,Achille Iolascon,Massimo Zollo +20 more